Uric acid as a cardiovascular risk factor in arterial hypertension

被引:113
作者
Puig, JG
Ruilope, LM
机构
[1] Hosp La Paz, Div Internal Med, Madrid, Spain
[2] Hosp 12 Octubre, Div Nephrol, E-28041 Madrid, Spain
关键词
uric acid; hypertension; insulin; oxygen species; cardiovascular risk factors;
D O I
10.1097/00004872-199917070-00001
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background Increased serum urate concentrations is a frequent finding in patients with hypertension. Since hyperuricaemia is associated with obesity, renal disease, hyperlipidaemia, and atherosclerosis the question as to whether serum urate is a cardiovascular risk factor per se has remained elusive. In considering the relationship between uric acid and hypertension three aspects should be answered: (a) the significance of hyperuricaemia; (b) the pathophysiological mechanism of the association; and (c) whether hyperuricaemia is deleterious. Significance of hyperuricaemia Several arguments favour the concept that increased serum urate in hypertensive patients most likely reflects renal vascular involvement. Pathophysiological mechanism Hyperuricaemia is accompanied by a relatively diminished uric acid excretion rate in hypertensive patients. Selective insulin resistance and hyperinsulinism estimulates the tubular sodium-hydrogen exchanger and facilitates the active reabsorption of urate. Is hyperuricaemia deleterious? In addition to the renal (urolithiasis) and articular disturbances that hyperuricaemia may cause, vascular damage due to arterial hypertension may limit the availability of oxygen for ATP synthesis. Tissue hypoxia determines increased adenine nucleotide degradation which ends in uric acid overproduction. The formation of uric acid is accompanied by an enhanced synthesis of reactive oxygen species which play a significant role in tissue damage. The hypothesis that hyperuricaemia indicates hypertensive vascular damage is plausible and if unequivocally demonstrated may contribute to delineate evidence-based therapeutic strategies for hypertensive-hyperuricaemic patients. I Hypertens 1999, 17:869-872 (C) Lippincott Williams & Wilkins.
引用
收藏
页码:869 / 872
页数:4
相关论文
共 30 条
[1]  
[Anonymous], 1996, DIS KIDNEY
[2]   HYPERURICEMIA AS A RISK FACTOR OF CORONARY HEART-DISEASE - THE FRAMINGHAM-STUDY [J].
BRAND, FN ;
MCGEE, DL ;
KANNEL, WB ;
STOKES, J ;
CASTELLI, WP .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 121 (01) :11-18
[3]  
Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4
[4]  
CAPUCCIO FP, 1993, JAMA-J AM MED ASSOC, V270, P354
[5]   NEW USES FOR ALLOPURINOL [J].
DAY, RO ;
BIRKETT, DJ ;
HICKS, N ;
MINERS, JO ;
GRAHAM, GG ;
BROOKS, PM .
DRUGS, 1994, 48 (03) :339-344
[6]  
DEFRONZO RA, 1981, DIABETOLOGIA, V21, P165, DOI 10.1007/BF00252649
[8]  
FOX IH, 1985, J LAB CLIN MED, V106, P101
[9]   SERUM URIC ACID IN RELATION TO AGE AND PHYSIQUE IN HEALTH AND IN CORONARY HEART DISEASE [J].
GERTLER, MM ;
GARN, SM ;
LEVINE, SA .
ANNALS OF INTERNAL MEDICINE, 1951, 34 (06) :1421-1431
[10]   A RANDOMIZED CONTROLLED TRIAL OF ALLOPURINOL IN CORONARY-BYPASS SURGERY [J].
JOHNSON, WD ;
KAYSER, KL ;
BRENOWITZ, JB ;
SAEDI, SF .
AMERICAN HEART JOURNAL, 1991, 121 (01) :20-24